---
figid: PMC7200761__41389_2020_228_Fig7_HTML
figtitle: Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma
  cells by activating MAPK signaling via IGF1R
organisms:
- NA
organisms_ner:
- Homo sapiens
pmcid: PMC7200761
filename: 41389_2020_228_Fig7_HTML.jpg
figlink: pmc/articles/PMC7200761/figure/Fig7/
number: F7
caption: One of the mechanisms by which loss of HAT1 drives acquired BRAFi resistance
  is via IGF1R-dependent activation of MAPK signaling pathway, and the pharmacological
  targeting of IGF1R or ERK1/2 restores the sensitivity of melanoma cells with reduced
  HAT1 expression levels to BRAFi.
papertitle: Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma
  cells by activating MAPK signaling via IGF1R.
reftext: Suresh Bugide, et al. Oncogenesis. 2020 May;9(5):44.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9454672
figid_alias: PMC7200761__F7
figtype: Figure
redirect_from: /figures/PMC7200761__F7
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7200761__41389_2020_228_Fig7_HTML.html
  '@type': Dataset
  description: One of the mechanisms by which loss of HAT1 drives acquired BRAFi resistance
    is via IGF1R-dependent activation of MAPK signaling pathway, and the pharmacological
    targeting of IGF1R or ERK1/2 restores the sensitivity of melanoma cells with reduced
    HAT1 expression levels to BRAFi.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - BRAF
  - HAT1
  - EPHB2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - IGF1R
  - Vemurafenib
  - Dabrafenib
  - Melanoma
---
